Advertisement
Canada markets closed

  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CAD/USD

    0.7308
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • Bitcoin CAD

    85,852.61
    +4,844.95 (+5.98%)
     

  • CMC Crypto 200

    1,358.43
    +81.45 (+6.38%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     

  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Vitality Biopharma Sparks Canadian Cannabinoid Genetics R&D

Baystreet.ca
Updated

Canada’s role in the emerging cannabinoid revolution just took another step forward this week—further highlighting that the country will be at the forefront of development for the foreseeable future. The makers of a new form of cannabinoid prodrugs called “cannabosides,” have officially announced they’re launching a Canadian subsidiary focused on cannabinoid genetics research and development. Vitality Biopharma, Inc. (OTC: VBIO) announced the formation of a ... Click here to view full article